Pure Global
NCT06113367

Immunotherapy in Upper Tract Urothelial Carcinoma

Carcinomes urothéliaux Des Voies excrétrices supérieures traitées en Vie réelle Par immunothérapie (VESUVIO) : étude rétrospective Nationale
Assistance Publique - Hôpitaux de Paris·ClinicalTrials.gov·otherNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Urothelial Carcinoma
Drug/Device/Intervention
Evaluation of anti-PD-(L)1 immunotherapy efficacy
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Assistance Publique - Hôpitaux de Paris
Timeline & enrollment
Phase
N/A
Start date
Nov 01, 2023
End date
Feb 28, 2024
Enrollment
350 participants
Primary outcome

Overall survival on anti-PD-(L)1 immunotherapy

Summary

Upper-tract urothelial carcinoma (UTUC) is a rare tumor. Standard treatment of localized
 disease is most often radical nephroureterectomy.
 
 In advanced/metastatic disease, treatments follow the standards for urothelial carcinoma
 including platinum-based chemotherapy and anti-PD(L)1 (Programmed death (ligand) 1)
 immunotherapy, with no regard as to the primary disease site (bladder or upper tract). Given
 the rarity of UTUC, efficacy data in the UTUC subgroup of advanced urothelial carcinoma is
 scarce.
 
 UTUC show distinct pahological and molecular features, including higher prevalence of
 microsatellite instability and of abnormalities in the FGFR (fibroblast growth factor
 receptors) gene family. These specific features may impact outcomes of immunotherapy in
 advanced/metastatic UTUC.

ICD-10 classifications
Carcinoma in situ: Other and unspecified urinary organsMalignant neoplasm of ureterMalignant neoplasms of urinary tractMalignant neoplasm: Overlapping lesion of urinary organsMalignant neoplasm: Urethra
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06113367
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06113367 through Pure Global AI's free database. This phase not specified trial is sponsored by Assistance Publique - Hôpitaux de Paris and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 350 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.